SS-31 Research Guide

SS-31 (Elamipretide): A Research Guide to the Mitochondrial-Targeted Tetrapeptide

SS-31, also known in pharmaceutical development as elamipretide, is one of the most extensively studied mitochondria-targeted research peptides in the published literature. This small synthetic tetrapeptide has attracted sustained scientific attention because of an unusual mechanism: rather than binding a protein receptor, it binds cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. This article reviews what the published research shows about SS-31's structure, mechanism, and experimental findings — strictly as a research-use-only reference.

Research Use Only. The material discussed here is intended solely for laboratory research. Nothing in this article constitutes medical advice, and no therapeutic claims are made. Research-grade SS-31 is not an approved drug product.

What Is SS-31?

SS-31 is a synthetic aromatic-cationic tetrapeptide with the amino acid sequence D-Arg-Dmt-Lys-Phe-NH2 and a molecular weight of approximately 640 g/mol. It was originally identified by researchers Hazel Szeto and Peter Schiller at Cornell University, who were investigating opioid signaling compounds when they observed that certain small peptides concentrated selectively inside mitochondria (Zhao et al., 2004).

Several structural features distinguish SS-31 from conventional peptides studied in laboratory settings:

• D-amino acids and methylated tyrosine (Dmt): These modifications confer resistance to proteolytic degradation, a property documented in the early characterization work (Szeto, 2006).
• Alternating charge pattern: The molecule's arrangement of basic and aromatic residues enables it to cross cellular membranes and accumulate within mitochondria at concentrations reported to exceed 1,000-fold relative to the cytosol (Szeto, 2006).
• Lipid-first targeting: The developers described SS-31 as among the first compounds known to target a membrane lipid rather than a protein, a distinction emphasized in subsequent reviews (Szeto and Birk, 2014).

How SS-31 Works: Cardiolipin Binding and Cristae Stabilization

The central mechanistic claim in the SS-31 literature is its interaction with cardiolipin. Cardiolipin is a cone-shaped phospholipid essentially unique to the inner mitochondrial membrane, where it plays a structural role in forming cristae — the folded membrane structures that house the electron transport chain — and in organizing respiratory complexes into supercomplexes (Szeto and Birk, 2014).

According to fluorescence and NMR studies, SS-31's two basic residues interact electrostatically with cardiolipin's phosphate head groups, while its aromatic residues associate with the lipid's fatty-acid tails (Szeto and Birk, 2014). This binding is proposed to:

1. Stabilize cardiolipin against oxidation. Cardiolipin is susceptible to peroxidation under conditions of elevated reactive oxygen species, and its oxidation is associated with disrupted electron transport. By associating with cardiolipin, SS-31 is hypothesized to protect it from oxidative damage.
2. Preserve cristae architecture. In a rat model of kidney ischemia, SS-31 protected mitochondrial cristae structure during ischemic injury (Birk et al., 2013).
3. Support electron transport chain organization. By maintaining the lipid environment in which respiratory supercomplexes assemble, SS-31 is proposed to preserve the efficiency of oxidative phosphorylation.

A 2020 study using model lipid bilayers added a biophysical dimension: Mitchell and colleagues demonstrated that SS-31 binds membranes containing anionic lipids — cardiolipin most strongly — and alters their surface electrostatic properties, arguing that this membrane-level effect, rather than any single protein interaction, is central to the mechanism (Mitchell et al., 2020). Complementary work using chemical cross-linking and mass spectrometry mapped SS-31's protein contacts in mouse heart mitochondria, finding them concentrated among inner-membrane proteins that themselves depend on cardiolipin, including components of the ATP-synthesis machinery (Chavez et al., 2020).

Key Published Research on SS-31

Discovery and Mitochondrial Targeting

The foundational paper by Zhao et al. (2004), published in the Journal of Biological Chemistry, described the SS peptide series and demonstrated their selective concentration in mitochondria. A subsequent review by Szeto (2006) in the AAPS Journal consolidated the early pharmacological characterization, including the reported greater-than-1,000-fold mitochondrial accumulation.

Mitochondrial Energetics in Aging Models

Siegel et al. (2013), publishing in Aging Cell, reported that SS-31 rapidly improved mitochondrial energetics and skeletal muscle performance in aged mice. Notably, the same treatment produced no measurable change in young, healthy mice — a finding the authors interpreted as evidence that the peptide acts selectively on mitochondria that have already declined rather than altering healthy ones. The study documented increased maximum ATP production capacity and improved coupling efficiency of oxidative phosphorylation in aging skeletal muscle.

Ischemia and Cristae Protection

Birk et al. (2013), in the Journal of the American Society of Nephrology, demonstrated that SS-31 accelerated ATP recovery following ischemic injury by protecting mitochondrial cristae structure. In treated tissues, ATP levels recovered within one hour of reperfusion, compared with persistent deficits in untreated controls — an effect attributed to preservation of the cristae membranes that serve as the structural platform for oxidative phosphorylation.

Cytochrome c and Electron Transfer

A 2014 follow-up in the British Journal of Pharmacology extended the mechanism to the cytochrome c/cardiolipin complex, reporting that SS-31 promoted electron transfer through cytochrome c and increased ATP synthesis in isolated mitochondria.

Clinical Development Programs

SS-31 entered clinical development as elamipretide and has been evaluated in human studies of primary mitochondrial myopathy, heart failure, and Barth syndrome — a rare inherited disorder of cardiolipin remodeling. The TAZPOWER Phase III program in Barth syndrome showed trends toward cardiac improvement, though the primary endpoint was not met. In September 2025, the FDA granted accelerated approval to a pharmaceutical formulation of elamipretide (marketed as Forzinity) for Barth syndrome, making it the first mitochondria-targeted drug to receive FDA approval.

Important distinction: That regulatory approval applies exclusively to the pharmaceutical product for its approved indication. It does not transfer to research-grade SS-31, which is not an approved drug product and is supplied strictly for laboratory research use.

SS-31 Research Materials at NUPEPS PEPTIDES

NUPEPS PEPTIDES supplies SS-31 as a lyophilized research reference material in two quantities:

• SS-31 10MG (collegamento) — suitable for pilot-scale mitochondrial research assays
• SS-31 50MG (collegamento) — suitable for extended research programs requiring larger material quantities

Each batch is supplied with a Certificate of Analysis documenting purity (≥99%) and identity verification. All materials are for research use only.

Evaluating SS-31 Quality in a Research Setting

Because published findings on SS-31 depend on the material actually studied, researchers routinely verify several quality attributes before beginning experimental work:

• Identity confirmation: Mass spectrometry should confirm the expected molecular weight (~640 g/mol) and the D-Arg-Dmt-Lys-Phe-NH2 sequence, including the non-standard Dmt residue.
• Purity assessment: Reversed-phase HPLC is the standard method for quantifying peptide purity; NUPEPS reports ≥99% purity on its Certificates of Analysis.
• Batch documentation: A batch-specific Certificate of Analysis — rather than a generic or representative document — provides the traceability needed for reproducible research.
• Lyophilized format: Freeze-dried presentation supports stability during storage and controlled reconstitution for analytical handling.

These practices reflect general standards in peptide research procurement and are not specific to any single supplier.

Domande frequenti

What is the amino acid sequence of SS-31?

SS-31 is a tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. The D-amino acids and the dimethyltyrosine (Dmt) residue distinguish it from naturally occurring peptides and contribute to its proteolytic stability in experimental settings.

How does SS-31 differ from general antioxidants studied in mitochondrial research?

According to the published mechanism, SS-31 does not act primarily as a free-radical scavenger. Its described mode of action is structural: binding cardiolipin in the inner mitochondrial membrane and stabilizing the lipid environment of the electron transport chain (Szeto and Birk, 2014; Mitchell et al., 2020).

What does "cardiolipin binding" mean in practical research terms?

Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane. In the literature, SS-31's association with cardiolipin is studied as a means of preserving cristae morphology and respiratory supercomplex organization under experimental stress conditions.

Is research-grade SS-31 the same as the FDA-approved elamipretide product?

No. The FDA's September 2025 accelerated approval applies to a specific pharmaceutical formulation (Forzinity) for Barth syndrome. Research-grade SS-31 is a separate material supplied for laboratory use only and carries no regulatory approval for any use.

What analytical documentation accompanies NUPEPS SS-31?

Each batch includes a Certificate of Analysis reporting HPLC purity (≥99%) and mass spectrometry identity confirmation.

Is SS-31 intended for human or veterinary use?

No. NUPEPS SS-31 is supplied strictly as a research reference material for laboratory use only. It is not intended for human or veterinary use, and no therapeutic claims are made.

References

1. Zhao K, et al. "Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury." J Biol Chem. 2004;279(33):34682-34690.
2. Szeto HH. "Cell-permeable, mitochondrial-targeted, peptide antioxidants." AAPS J. 2006;8(2):E277-E283.
3. Birk AV, et al. "The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." J Am Soc Nephrol. 2013;24(8):1250-1261.
4. Siegel MP, et al. "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." Aging Cell. 2013;12(5):833-841.
5. Szeto HH, Birk AV. "Serendipity and the discovery of novel compounds that restore mitochondrial plasticity." Clin Pharmacol Ther. 2014;96(6):672-683.
6. Mitchell W, et al. "The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action." J Biol Chem. 2020;295(21):7452-7465.
7. Chavez JD, et al. "Chemical crosslinking mass spectrometry analysis of the mitochondrial SS-31 interactome." Proc Natl Acad Sci USA. 2020;117(26):15363-15373.
8. Tung et al. "Elamipretide: structure, mechanism and development." Int J Mol Sci. 2025. (Review consolidating the primary literature.)